Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy.
There were four recent publications, including the primary publication for CCTG CO.26: A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies.
In the race to find new ways to prevent and treat COVID-19, the Canadian Cancer Trials Group (CCTG) has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients.
The trial is called CCTG IC.8: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (COV-IMMUNO). IMM-101 is a preparation of safe, heat-killed bacteria that broadly stimulates the innate, or “first-response,” arm of the immune system. Researchers hope that boosting cancer patients’ immune systems with IMM-101 will protect them from developing severe COVID-19 and other dangerous lung infections.
CCTG is very pleased to announce that Dr. Sara Taylor is the 2020 recipient of the Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award.
This award honours young investigators who have participated in the Investigational New Drug (IND) Program and have significantly contributed to IND trial conduct within their institution. Individuals are nominated by their colleagues and the IND Director/Executive Committee to determine the awardee.